Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies

Hypertrophic cardiomyopathy (HCM) and primary restrictive cardiomyopathy (RCM) have a similar genetic background as they are both caused mainly by variants in sarcomeric genes. These “sarcomeric cardiomyopathies” also share diastolic dysfunction as the prevalent pathophysiological mechanism. Starting from the observation that patients with HCM and primary RCM may coexist in the same family, a characteristic pathophysiological profile of HCM with restrictive physiology has been recently described and supports the hypothesis that familiar forms of primary RCM may represent a part of the phenotypic spectrum of HCM rather than a different genetic cardiomyopathy. To further complicate this scenario some infiltrative (amyloidosis) and storage diseases (Fabry disease and glycogen storage diseases) may show either a hypertrophic or restrictive phenotype according to left ventricular wall thickness and filling pattern. Establishing a correct etiological diagnosis among HCM, primary RCM, and hypertrophic or restrictive phenocopies is of paramount importance for cascade family screening and therapy.


Introduction
Cardiomyopathies are a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction, due to a variety of causes that are frequently genetic [1]. They can be either confined to the heart ("primary cardiomyopathy") or part of generalized systemic disorders ("secondary cardiomyopathy"), often leading to cardiovascular death or progressive heart failure-related disability [1]. The most common cardiomyopathy is hypertrophic cardiomyopathy (HCM) caused by variants in sarcomeric (or sarcomere-related) genes, characterized by left ventricular hypertrophy in the absence of another cardiac, systemic, or metabolic disease capable of producing the magnitude of hypertrophy evident [2]. A key pathophysiological aspect of HCM is diastolic dysfunction, which can be severe enough to determine a restrictive left ventricular filling pattern [3], raising problems of differential diagnosis with primary restrictive cardiomyopathy (RCM). Some familial forms of primary RCM have been described in patients carrying variants in sarcomeric genes traditionally associated with HCM [4], and HCM and primary RCM may coexist in the same family [5]. This scenario is further complicated by classifications that group cardiomyopathies based only on ventricular morphology and function irrespective of etiology [6,7]. According to these phenotypic classifications, some infiltrative and storage diseases may be listed as either HCM or RCM depending on the degree of hypertrophy observed and left ventricular filling pattern (hypertrophic or restrictive phenocopies) [7]. This review focuses on morphological, functional, and genetic features of HCM and primary RCM, offering guiding principles for differential diagnosis between them and among cardiomyopathies that can present either with a hypertrophic or restrictive phenotype.

Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant heart disease caused by a broad variety of genetic variants involving mostly proteins of the cardiac sarcomere. Given its prevalence of 1:500 in the general population, it is considered the most common genetic cardiovascular disease [1,2]. A left ventricular wall thickness of at least 15 mm (or 13 mm in relatives) is considered sufficient for diagnosis, in the absence of other systemic or cardiac diseases capable of producing the magnitude of hypertrophy evident (e.g., hypertension and aortic stenosis) [2]. At least 1400 variants in numerous genes encoding proteins of the cardiac sarcomere responsible for (or associated with) HCM have been identified [8]. The most commonly involved genes are MYH7, MYBPC3 (these two genes include approximately 80% of all identified variants), TNNT2, and TNNI3. The majority of patients reveal increased wall thickness by early adulthood [9,10], however different variants can demonstrate substantial variability in age-related penetrance, resulting in delayed expression after the third decade of life, or even beyond mid-life [11,12]. The phenotype in the first-degree family members also shows a wide range of expression, underscoring the importance of other factors including modifier genes and epigenetics [13,14].
Twelve-lead ECG has traditionally been an integral part of non-invasive evaluation of patients with HCM [15,16]. The vast majority of patients show an abnormal ECG tracing, with a reported prevalence of ECG abnormalities of >90% [17]. Left ventricular hypertrophy, ST-segment depression, T wave inversion, pathologic Q waves, left atrial enlargement, and left axis deviation are among the striking ECG abnormalities [15]. Atrial fibrillation is reported in 20% of cases, being associated with heart failure progression [18][19][20]. On the contrary, a normal ECG may predict a less severe HCM phenotype and a better cardiovascular outcome [15,21,22]. Echocardiography is the primary non-invasive imaging technique for diagnosis and risk stratification of HCM [22]. One third of patients have resting left ventricular outflow tract obstruction (>30 mmHg) and another third have latent obstruction that can be unmasked during provocative maneuvers [23]. Mitral regurgitation is a common finding as the result of systolic anterior motion of the mitral valve, and together with diastolic dysfunction leads to the enlargement of the left atrium. Diastolic dysfunction can be severe enough to produce a left ventricular restrictive filling pattern, defined as the ratio of mitral peak velocity of early filling (E) to mitral peak velocity of late filling (A) ≥2 or an E-wave deceleration time ≤ 150 ms. Biagini et al., reported a restrictive left ventricular filling pattern in 5.9% of 239 consecutive HCM patients at baseline, with another 9.1% of them who developed this pattern during follow-up [3]. Another sign of severe diastolic impairment is the triphasic left ventricular filling pattern (showing an additional mid-diastolic filling wave) that can be found in up to one quarter of patients, particularly those with thin-filament gene variants [24]. Systolic function is usually normal or increased, until the development of the end-stage phase. Cardiovascular magnetic resonance (CMR) allows precisely measuring wall thickness (especially at the apex and lateral free wall), cardiac chamber volumes, and left ventricular mass. Myocardial fibrosis is revealed by the injection of gadolinium-based contrast agents in 65% of patients [25,26]. Diffuse and extensive late gadolinium enhancement at CMR, either quantified or estimated by visual inspection (comprising ≥ 15% of left ventricular mass) is now considered an established risk factor for sudden death [2]. Endomyocardial biopsy is not part of the routine diagnostic workup of HCM, but may instead be helpful when myocardial infiltration or storage disease is suspected. Histopathological features of HCM include myocyte disarray, increased interstitial fibrosis and abnormal intramural arterioles with thickened walls and narrowed lumen [27][28][29]. In a large autopsy-based study, coronary artery bridges were a frequent morphological component of phenotypically expressed HCM [30].
Patients' clinical courses are heterogeneous, ranging from benign to sudden cardiac death, being the leading cause of athletic field cardiac arrest in the USA, where it accounts for more than a third of fatalities [31,32]. Different profiles of heart failure in HCM may occur at any age due to diverse pathophysiological mechanisms, including left ventricular outflow obstruction and diastolic or global systolic ventricular dysfunction [23,33,34]. According to Melacini et al., nearly half of patients with advanced heart failure occur in the clinical setting of non-obstructive disease with preserved systolic function, presenting a particularly malignant prognosis with earlier symptom onset [29]. This "restrictive subgroup" of HCM patients show small ventricular cavities, markedly enlarged atria and mild left ventricular hypertrophy with a restrictive left ventricular filling pattern ( Figure 1). When hypertrophy is mild, differential diagnosis with RCM can be difficult and a phenotypic overlap between these two entities may exist. Evaluating 1226 patients from 688 families with HCM, Kubo et al. advanced the "restrictive phenotype" (i.e., no or minimal left ventricular hypertrophy of ≤15 mm and severe diastolic dysfunction) as part of the clinical spectrum of HCM [35]. The authors concluded that the "restrictive phenotype" is an uncommon presentation of HCM (19/1266, 1.5% of cases), associated with severe functional limitation and poor prognosis, resembling idiopathic RCM. Sarcomeric gene variants were identified in eight probands, including variants in MYH7 and TNNI3. However, not all family members with the same variant developed the "restrictive phenotype" suggesting that other genetic (e.g., modifier genes), epigenetic or environmental factors are involved. Our research group recently reported a novel missense variant in the MYL2 gene associated with HCM showing high incidence of restrictive physiology ( Figure 2) [36]. Specifically, 38% of MYL2 carriers in our kindred had a restrictive filling pattern, much higher than previously reported [3], and one patient showed the "restrictive phenotype" defined by Kubo et al. [35]. Probably linked to the severe diastolic dysfunction, up to 62% of MYL2 carriers experienced atrial fibrillation and many patients had a poor clinical outcome.

Primary Restrictive Cardiomyopathy
Primary RCM is a rare myocardial disease characterized by normal or decreased volume of both ventricles associated with biatrial enlargement, normal left ventricular wall thickness, impaired ventricular filling with restrictive physiology, and normal or nearnormal systolic function [1]. Since the first report of a familial form caused by a cardiac troponin I (TNNI3) variant [4], primary RCM was believed to be a sarcomeric disease and was labeled together with HCM as a sarcomeric cardiomyopathy ("sarcomyopathies") according to a genomic/postgenomic classification [37][38][39][40]. Successively, apart from a small subset of rare nonsarcomeric variants (myopalladin, filament-C, desmin, and alpha-beta crystallin [41][42][43][44]), mounting evidence supported this view. Moreover, "desminopathies" (i.e., familial RCM with variants in the desmin gene) should be classified as a separate and secondary cardiomyopathy, given the almost invariable skeletal muscle involvement producing a skeletal myopathy [43]. The most common sarcomeric gene variants associated with primary RCM involve troponin T (TNNT2), alpha cardiac actin (ACTC), myosinbinding protein C (MYBPC3), tropomyosin 1 (TPM1), and myosin light chain 2 (MYL2) and 3 (MYL3) [45][46][47][48]. Moreover, TNNI3, MYH7, and MYL2 variants were reported as responsible for some familial cases of HCM with "restrictive phenotype" (phenotypes diagnostic of RCM) [4,36]. The coexistence of HCM and RCM phenotypes in the same families with the same disease-causing variants led to the hypothesis that familiar forms of RCM may represent a part of the phenotypic spectrum of HCM rather than a different genetic cardiomyopathy [5,49].
The phenotypic expression of other cardiomyopathies (e.g., infiltrative and storage disorders, endomyocardial fibrosis and sarcoidosis) may mimic primary RCM [1,50,51]. However, in primary RCM the morphologic and hemodynamic abnormalities occur in the absence of specific histopathological changes [50,51] and possible findings include interstitial fibrosis, myocyte hypertrophy, and myocardial disarray as in HCM [5,38,52].
The key aspect of primary RCM is the impairment of the ventricular filling dynamics that ultimately lead to the increase of ventricular end-diastolic pressures and atrial dilation. Such diastolic impairment is responsible for the development of progressive heart failure symptoms (dyspnea, fatigue, and exercise intolerance). Cardiac catheterization shows increased ventricular filling pressures with the typical dip-and-plateau or square-root sign; left ventricular diastolic pressure is usually 5 mmHg higher compared to the right one due to imbalanced involvement and compliance of the two chambers [51]. Equalization of ventricular diastolic pressures is more typical of constrictive pericarditis but it may be present and does not rule out the diagnosis of primary RCM [51,53]. Differential diagnosis between these two conditions is usually straightforward: history of chronic pericarditis, cardiac surgery, or chest irradiation favors the diagnosis of a constrictive pericarditis. Non-invasive diagnostic testing (echocardiography, CMR, and cardiac computed tomography (CT)) or invasive hemodynamic study are able to unveil characteristic features of constrictive pericarditis including a thickened pericardium (>4 mm), interventricular dependence, and dissociation between intracardiac and intrathoracic pressures during respiration [53]. CMR is also helpful to differentiate primary RCM with secondary forms of RCM due to infiltrative or storage diseases which show typical radiological findings (see below) ( Figure 3). Fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is indicated in case of clinical suspicion of sarcoidosis [54]. As happened for all the other principal cardiomyopathies, before the understanding of molecular genetics of the disease primary RCM was referred to as "idiopathic" RCM [50]. The largest series is derived from the study of Ammash et al., who described 94 cases of idiopathic RCM collected between 1979 and 1996, after excluding patients with known ischemic, hypertensive, valvular, congenital, or pericardial heart disease and other conditions such as amyloidosis, hemochromatosis, and eosinophilic syndrome [55]. According to the study results, idiopathic RCM can occur at any age and mostly in women. The ECG was almost invariably abnormal, with the majority of patients showing atrial fibrillation (74%) and nonspecific ST-T wave abnormalities (80%); intraventricular conduction delay was reported in 19% of patients and premature ventricular beats in 14%. Of note, none of the patients had left ventricular hypertrophy (typical of HCM) or low QRS voltages (typical of amyloidosis, see below). At the echocardiogram all patients showed biatrial enlargement, nondilated ventricles with normal wall thickness; transmitral valve Doppler showed either E-wave deceleration time of <150 ms or an E/A ratio > 2. None of the biopsy specimens demonstrated amyloid or iron deposition, caseating granulomas, eosinophilic or lymphocytic infiltrates, or any interstitial inflammatory changes.

Cardiomyopathies with either Hypertrophic or Restrictive Phenotype
Some infiltrative and storage diseases may present as phenocopies of either HCM or primary RCM, according to the degree of hypertrophy observed and left ventricular filling pattern (Figure 4). If maximal left ventricular wall thickness is at least 15 mm, they must be differentiated from sarcomeric HCM. Otherwise, the restrictive physiology inherent to the pathological process of myocardial infiltration or storage yields a phenotype similar to that of primary RCM. Unmasking the underlying disease and going beyond the ventricular morphology and function, is crucial in order to establish prognosis, guide reproductive choices, and offer specific therapy to the patient. Age of onset is among the factors to consider for differential diagnosis: for instance, glycogen storage diseases are more common in infants, whereas ATTRwt amyloidosis involves predominantly men over the age of 65 years [56,57]. Herein we describe the cardiomyopathies that can show either a hypertrophic or a restrictive phenotype. Table 1 reports the full list of HCM and primary RCM phenocopies, and Table 2 summarizes the common diagnostic findings of HCM, primary RCM, amyloidosis, Fabry disease, and glycogen storage diseases.

Amyloidosis
Amyloidosis is a systemic syndrome that represents the archetype of the infiltrative form of RCM. Extracellular deposition of insoluble amyloid fibrils involves a variety of organs including the heart, leading to cardiomyocyte separation, cellular toxicity, and apoptosis. Overall, these morphological changes increase myocardial stiffness causing diastolic disfunction and heart failure. The three most common types of amyloidosis affecting the heart ("cardiac amyloidosis") are AL, ATTRwt, and mutant transthyretin (ATTRm) amyloidosis. AL amyloidosis is a rare hematological disorder, in which there is an increased production of monoclonal kappa or lambda light chains that tend to misfold favoring tissue deposition. Transthyretin is a protein with tetrameric configuration, produced mainly in the liver; its monomers have amyloidogenic properties. ATTRm amyloidosis is a heritable autosomal disorder caused by variants in the TTR gene that increase the likelihood of the TTR tetramer to dissociate into monomers and form amyloid fibrils. In the absence of TTR pathogenic variants, spontaneous dissociation of TTR tetramers may occur (usually later in life), determining ATTRwt amyloidosis (senile amyloidosis). AL amyloidosis is rare and has an estimated prevalence of 8 to 12 per million [59][60][61], although emerging data suggest that ATTRwt amyloidosis is not uncommon: it may affect up to 13% of patients hospitalized for heart failure with preserved ejection fraction [62]. Variants in the TTR gene causing ATTRm amyloidosis are relatively rare but are endemic in some geographic regions (e.g., Portugal and Sweden) [63].
Clinical presentation is useful, per se, in the differential diagnosis with sarcomeric cardiomyopathies, as patients with amyloidosis show variable extracardiac organ involvement. Peripheral and autonomic neuropathy, carpal tunnel syndrome, macroglossia, nephropathy, and hepatopathy are red flags for amyloidosis and should be sought in all patients [64]. At the ECG, low voltages are reported in 20-60% of patients and mostly in those with AL amyloidosis [65,66]. Pseudoinfarction patterns (Q waves or QS complexes) are common (70% of cases), as they also are in HCM [15,67]. A significant percentage of patients with amyloidosis develop progressive atrioventricular conduction disturbances or bundle branch blocks [67]. Echocardiography reveals a concentric thickening of the left ventricular free wall and septum, that is usually greater in patients with ATTRwt amyloidosis [68]. Unlike HCM, right ventricular free wall, valves and atrial septum are also thickened. According to a study by Quarta et al. who analyzed 172 patients with AL, ATTRm or ATTRwt amyloidosis, a third of the overall population (n = 63) showed a mean left ventricular wall thickness (almost identical to the interventricular septum thickness given the concentric hypertrophy) of ≤15 mm (range 11.5-15 mm), and the other two thirds >15 mm [68]. A restrictive filling pattern was found in 35% of patients. From these data it is clear how the phenotype of patients with amyloidosis may mimic either HCM or primary RCM. Some peculiar although nonspecific echocardiographic findings of amyloidosis that may guide differential diagnosis are the following: right ventricular free wall, valves and atrial septum thickening, pericardial effusion and "granular" appearance of the myocardium [69]. Early signs of cardiac amyloid infiltration are the reduced basal longitudinal strain compared to the normal or supranormal apical longitudinal strain ("apical sparing") and low septal and lateral early diastolic mitral annular velocities (E'-wave) at tissue-Doppler echocardiography [64,70]. CMR can provide further clues to the diagnosis of amyloidosis by showing a characteristic diffuse subendocardial late gadolinium enhancement ("zebra pattern"), and difficulty in nulling the myocardial signal on phase sensitive inversion recovery sequences [71][72][73]. Bone scintigraphy imaging has recently gained crucial relevance, since it has high specificity and a positive predictive value of 100% for transthyretin amyloidosis in case of moderate to high tracer uptake [64]. In the absence of detectable monoclonal protein in serum or urine, bone scintigraphy allows non-histological diagnosis of transthyretin amyloidosis [74]. However, tissue diagnosis remains the gold standard. Congo red staining binds to the deposits of amyloid fibrils and yields characteristic apple-green birefringence under polarized light microscopy. Electron microscopy demonstrates randomly oriented and non-branching fibrils and subsequently immunohistochemistry or laser microdissection/mass spectroscopy allows the subtyping of amyloid fibril [75,76].
The treatment of amyloidosis goes beyond the purpose of the present review, but novel specific therapies improving cardiac and neurological outcomes have been recently approved and its recognition is therefore of paramount importance [77,78].

Fabry Disease
Fabry disease is a lysosomal storage disease with an X-linked recessive inheritance caused by variants in the GLA gene, that determine an absent or deficient activity of lysosomal alpha galactosidase A. As a result, globotriaosylceramide accumulate within virtually all cell types' lysosomes, leading to cellular death, inflammation, oxidative stress, and fibrosis; cardiomyocyte hypertrophy results from increased concentrations of sphingolipid and vascular smooth muscle cell proliferation [79]. The prevalence of Fabry disease is estimated to be 1/3000-1/8000 newborns [80,81]. Indeed, near 1% of HCM population can be newly diagnosed with Fabry disease when screened for this condition [82]. First signs of the disease appear during childhood or early adulthood in men; women are diagnosed later in life and show a better prognosis, considering the pattern of inheritance of the disease (X-linked recessive transmission) [79]. In adults, clinical signs of Fabry disease include a variable combination of kidney, neurological, and cardiac dysfunctions. Cardiac symptoms occur in the majority of patients, and include dyspnea, heart failure, angina caused by microvascular dysfunction, palpitations, and syncope [83]. Patients with Fabry disease most often present with left ventricular hypertrophy, sometimes as a predominant or isolated feature ("cardiac variant") [81,84]. Left ventricular hypertrophy is the most frequent cardiac sign, reported in over a half of men and one third of women [83]. Other diagnostic red flags for Fabry disease are kidney disease, stroke, angiokeratoma corporis diffusum, and cornea verticillate [79,85]. Arrhythmic manifestations include chronotropic incompetence, sinus node dysfunction, advanced atrioventricular block, atrial fibrillation, ventricular tachycardia, and ventricular fibrillation leading to sudden death [86].
The electrocardiogram often displays increased QRS voltages as the result of the deposition within the cardiomyocytes rather than in the interstitium as it occurs in infiltrative disease (e.g., amyloidosis) characterized on the contrary by low QRS voltages. Other ECG changes that can be seen in Fabry disease patients include a short PR interval, sinus bradycardia, atrioventricular conduction disturbances, bundle branch blocks, pathologic Q waves, negative T waves, and atrial fibrillation [81,83,87,88]. Supraventricular and ventricular arrhythmias are common in Fabry disease and may occur even in the prehypertrophic phase before any clinical or cardiac imaging abnormalities [81,89]. At the echocardiogram, left ventricular hypertrophy is frequently encountered (almost invariably concentric), without left ventricular outflow obstruction or systolic dysfunction [90]. However, asymmetrical hypertrophy and subaortic obstruction have also been reported, mimicking the phenotypical and clinical features of sarcomeric HCM [91]. Other characteristics that may be documented are left atrial enlargement, valvular thickening and right ventricular hypertrophy [90,91]. These latter findings are similar to those of patients with amyloidosis, but further similarities between Fabry disease and amyloidosis exist. In fact, even in Fabry disease the reduced tissue-Doppler velocities at the mitral annulus can be the earliest signs of intrinsic myocardial relaxation impairment, preceding left ventricular hypertrophy [92]. Diastolic dysfunction progressively worsens until the development of a restrictive filling pattern [79]. Mid-mural late gadolinium enhancement on basal segment of the inferolateral left ventricular free wall is a typical finding at the CMR, often occurring on a non-hypertrophied wall [93]. Conversely, in HCM the site of predilection for LGE accumulation is the part with the greater hypertrophy [94]. Moreover, T1 mapping helps in the refinement of differential diagnosis with either HCM or amyloidosis. Sphingolipid storage in the myocardium yields low native T1 values which are specific for Fabry disease, as opposed to the other two conditions [95,96]. Definite diagnosis of Fabry disease is reached through the demonstration of decreased/absent serum or leukocyte alpha galactosidase A activity or pathogenic variants in the GLA gene. In addition, endomyocardial biopsy can identify histological alterations by showing the accumulation of the degradation product of globotriaosylceramide in the sarcoplasm of myocytes, forming concentric lamellar bodies [85,97]. Although the clinical response is not always optimal, enzyme replacement therapy may ameliorate symptoms and renal function, potentially reducing left ventricular hypertrophy, cardiac events, stroke, and overall death [98][99][100][101].

Glycogen Storage Diseases
Glycogen storage diseases are a group of inherited genetic disorders that cause glycogen to be improperly accumulated in the body. Although they are listed as cardiomyopathies that can also have a restrictive phenotype [7,51], patients affected with glycogen storage diseases typically show a marked left ventricular hypertrophy and must be differentiated mainly from HCM. This is particularly true for Danon disease (caused by deficiency of lysosome-associated membrane protein 2-LAMP 2) in which the hypertrophy can be so extreme as to reach 65 mm of left ventricular maximal wall thickness [102]. These morphological findings correspond to increased QRS voltages and T wave abnormalities at the ECG. Excess glycogen accumulates in cardiomyocytes and skeletal muscle fibers leading to formation of vacuoles that stain positive with periodic Acid Schiff [85]. In addition to skeletal and cardiac muscle involvement, mild to moderate mental retardation is frequently observed.
PRKAG2 syndrome is another type of glycogen storage disease, whose presentation includes skeletal myopathy, marked cardiac hypertrophy, arrhythmias, and conduction defects [85]. Left ventricular hypertrophy is often progressive and associated with both diastolic and systolic heart failure [103]. Maximal ventricular wall thickness varies widely among different patients, ranging from normal values to over 40 mm [104][105][106]. A restrictive filling pattern, left ventricular outflow tract obstruction, and dilated progression are leading causes of cardiac transplant or death [104,105,107]. Its key aspect is the association with Wolff-Parkinson-White syndrome (characterized by a short PR interval, ventricular pre-excitation, and supraventricular tachycardia), together with possible advanced atrioventricular blocks requiring pacemaker implantation. CMR patients with PRKAG2 syndrome may show LGE only in the advanced stages, together with high T1 values caused by fibrosis [108].
The heart is also part of the clinical spectrum of Pompe disease (acid maltase deficiency or glycogen storage disease type II) [57]. This disorder usually has an infantile onset, producing massive cardiac hypertrophy in neonatal and pediatric ages, able to determine left ventricular outflow tract obstruction. Diastolic dysfunction is generally present and systolic dysfunction can be seen later on [57]. Adult-onset acid maltase deficiency is a rare variant of the disease: as it seldom affects the heart, the cardiac phenotype of adults with this condition is poorly characterized [109]. The morphology of the heart of patients diagnosed with glycogen storage disease type III, also known as Cori disease, usually mimics HCM but can show restrictive physiology [51,110].

Conclusions
HCM and primary RCM have a similar genetic background as they are both sarcomeric cardiomyopathies, and significant phenotypic overlap can exist between them. Patients with HCM and primary RCM may coexist in the same family and a new category of HCM with restrictive physiology has been recently described. One hypothesis is that familiar forms of primary RCM may represent a part of the phenotypic spectrum of HCM rather than a different genetic cardiomyopathy. To further complicate this delicate scenario some infiltrative and storage diseases may show either a hypertrophic or restrictive phenotype (HCM and primary RCM phenocopies) according to left ventricular wall thickness and filling pattern. Establishing a correct diagnosis is of paramount importance for cascade family screening and therapy.
Author Contributions: R.V., D.C., and C.C. contributed to the design of the work and R.V. drafted the manuscript. A.A., C.B., A.C., A.Z., P.M., G.T., A.R., D.C., and C.C. critically revised the manuscript. All gave final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.

Data Availability Statement:
No new data were created or analyzed in this study. Data sharing is not applicable to this article.